Although the correlate of protection is unknown, the findings show that standard doses should be used in infants.

LYON, France, March 21, 2023 -- EDAP TMS SA (EDAP) (“the Company”), a global leader in robotic energy-based therapies, today announced a recent presentation of positive results from a large, ...

Shares of UNITY Biotechnology UBX crashed 28.8% yesterday, following mixed results from a mid-stage non-inferiority study of its lead candidate, intravitreal UBX1325 compared with Regeneron’s REGN ...

In the present trial, the non-inferiority margin was 0.4, meaning that efsitora wasn’t worse than degludec at reducing HbA1c. Efsitora vs degludec in adults with type 2 diabetes Like the ...